Previous 10 | Next 10 |
LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. St...
XOMA (XOMA) earned a $1M milestone payment from Agenus (AGEN) related to Merck's advancement of MK-4830 into a Phase 2 study in patients with advanced non-small cell lung cancer previously treated with anti-programmed cell death receptor ligand 1 therapy.MK-4830 is part of the company's first...
EMERYVILLE, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned a $1 million milestone payment from Agenus Inc. (NASDAQ: AGEN) related to Merck’s advancement of MK-4830 into a Ph...
Agenus ([[AGEN]] +0.3%) discovered checkpoint antibody MK-4830 enters Phase 2 study, thus triggering a milestone payment of $10M from Merck ([[MRK]] +1.0%).The antibody is designed to target immune-suppressive myeloid cells in the tumor microenvironment for the treatment of adv...
$10M milestone payment from Merck triggered Agenus is eligible for up to an additional $85 million in milestones plus royalties on sales LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of check...
AGEN1181 : New clinical responses and intratumoral Treg depletion AGEN 1777 ( TIGIT ) is Fc enhanced for optimized immune performance & broader benefit AGEN2373 (anti-CD137) : Clinical benefit with no liver toxicity Allogeneic iNKT...
Biotech Penny Stocks to Watch In November 2020 Biotech penny stocks have been making some big headway in the market in the past six months. Following the advent of Covid, many investors began to hedge bets on biotech stocks for the future. While some stocks that are dealing with...
LEXINGTON, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the appoint...
Shares of Agenus (NASDAQ: AGEN) , a clinical-stage immunotherapy company, rose by as much as 9.2% during the first half of Monday's trading session. The drugmaker's stock perked up in early morning action today in response to the news that the first COVID-19 patient had been dosed w...
Allogeneic (off the shelf) iNKT cell therapy targets patients with moderate to severe COVID-19 iNKT cells designed to clear SARS-CoV-2 virus while reducing harmful inflammation LEXINGTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology com...
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a co...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-07-18 12:11:22 ET Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cance...